Author: Olin, Rebecca ; Hahn, Theresa ; Singh, Anurag ; De Lima, Marcos ; Verdonck, Leo F. ; Battiwalla, Minoo ; Assal, Amer ; Koc, Yener ; Byrne, Michael ; Bolaños-Meade, Javier ; Wang, Hai-Lin ; Abdel-Azim, Hisham ; Bhatt, Vijaya Raj ; Kharfan-Dabaja, Mohamed A. ; Bashey, Asad ; Kanakry, Christopher G. ; Ganguly, Siddhartha ; Daly, Andrew ; Cairo, Mitchell ; Olsson, Richard F. ; Patel, Sagar ; Shaffer, Brian C. ; Litzow, Mark ; McGuirk, Joseph ; Weisdorf, Dan ; Rashidi, Armin ; Nishihori, Taiga ; Holland, H. Kent ; Ringden, Olov ; Maertens, Johan ; Hildebrandt, Gerhard C. ; Lazarus, Hillard M. ; Hamadani, Mehdi ; Nathan, Sunita ; Solh, Melhem ; Bajel, Ashish ; Murthy, Hemant S. ; Diaz, Miguel-Angel ; Hashmi, Shahrukh ; Farhadfar, Nosha ; Palmisiano, Neil ; Lee, Jong-Wook ; Schultz, Kirk R. ; Gale, Robert P. ; Zhang, Mei-Jie ; Saber, Wael ; Waller, Edmund K. ; Martino, Rodrigo ; Beitinjaneh, Amer M. ; Seo, Sachiko ; Cutler, Corey ; Rowe, Jacob ; Munker, Reinhold ; Hossain, Nasheed ; Khera, Nandita ; Rizzieri, David ; Grunwald, Michael R. ; Aljurf, Mahmoud ; Pidala, Joseph ; Cahn, Jean-Yves ; Wagner, John ; Bejanyan, Nelli ; Oran, Betul ; Nakamura, Ryotaro ; Savoie, Mary Lynn ; Ciurea, Stefan ; Copelan, Edward ; Romee, Rizwan ; Stockerl-Goldstein, Keith ; Sandmaier, Brenda M.

AbstractHLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

01 Apr 2017·Biology of Blood and Marrow TransplantationQ2 · MEDICINE

Human Leukocyte Antigen–Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis

Q2 · MEDICINE

Article

Author: Lacerda, Marcelo Pitombeira de ; Hamerschlak, Nelson ; Silva, Roberto L ; Rocha, Vanderson ; Pereira, André Domingues ; Macedo, Maria C M A ; Arrais Rodrigues, Celso ; Novis, Yana ; Esteves, Iracema ; Schmidt Filho, Jayr ; Nascimento, Marina M ; Fonseca, Marina

Reduced-intensity-conditioned allogeneic stem cell transplantation (SCT) remains a potentially curative approach for patients with relapsed/refractory Hodgkin lymphoma (HL) after an autologous stem cell transplantation. In the absence of an HLA-identical donor, haploidentical SCT (haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy) has been evaluated with favorable preliminary results. We evaluated 24 patients who underwent haplo-SCT for relapsed/refractory HL. The conditioning regimen consisted of cyclophosphamide, fludarabine, and total body irradiation. Graft-versus-host disease (GVHD) prophylaxis consisted of a calcineurin inhibitor, mycophenolate mofetil, and PT-Cy (50 mg/kg/day for 2 days) for all patients. After a median follow-up of 2 years, the cumulative incidence (CI) of nonrelapse mortality was 26% and the CI of grades II to IV acute GVHD and chronic GVHD were 17% and 24%, respectively. Estimation of progression-free and overall survival at 2 years were 54% and 66%%, respectively. Haplo-SCT is a valuable option for relapsed/refractory HL patients after a failed autologous SCT, with favorable survival and relatively low risk of GVHD.

100 Deals associated with Mycobacterium tuberculosis derived antigens(Vakzine)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Tuberculosis	IN	Serum Institute of India Pvt Ltd.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diagnostic agents	NDA/BLA	EU	Vakzine Projekt Management GmbH	17 Oct 2024
Tuberculosis	NDA/BLA	EU	Vakzine Projekt Management GmbH	17 Oct 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Mycobacterium tuberculosis derived antigens(Vakzine)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation